[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Public ClinicalTrials.gov record NCT01717391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
\[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.
Study identification
- NCT ID
- NCT01717391
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Feb 28, 2016
- Completion
- Apr 29, 2017
- Last update posted
- Mar 25, 2019
2012 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Uterine Cervical Neoplasms trials
Other public records listing Uterine Cervical Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT07214506: Human Papillomavirus (HPV) Self-Sampling Options to Promote Equity Not yet recruiting
- NCT04389632: A Study of Sigvotatug Vedotin in Advanced Solid Tumors Recruiting
- NCT07011836: Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women Recruiting
- NCT06400472: A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Recruiting
- NCT00579163: Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers Active, not recruiting
- NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01717391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01717391 live on ClinicalTrials.gov.